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Retinopathy of Prematurity: 
Incidence and Severity in Hawaii 
John H. Drouilhet MD, Susan Pelke RN, Donald Sroat MD 
Malcolm lng MD, Byron Wong MD, Gregg Kokame MD and David Easa MD 
Because survival of low birth-weight infants requiring inten-
sive care has improved recently, particularly since the ad-
vent of exogenous surfactant therapy, we reviewed our 
experience at Kapiolani Medical Center for Women and 
Children (KMCWC) from 1989 to1991 to determine if the 
incidence of retinopathy of prematurity (ROP), a serious long-
term complication, had also increased. During this 3-year 
period, threshold disease, the ROP stage in which cryosurgery 
is recommended, occurred only in infants ~ 1000 grams. 
Seventy- four infants~ 1000 grams were diagnosed with ROP 
of any stage. Sixteen eyes (9 infants) reached threshold; 14 
were treated with cryosurgery. Six of these eyes have useful 
vision on follow up; 8 do not. Exogenous surfactant therapy 
had no significant effect on ROP incidence or severity in our 
series. Although ROP incidence did not increase during this 
review period, it remains a serious problem in high-risk 
premature infants in our Newborn Intensive Care Unit. 
Introduction 
Retinopathy of prematurity (ROP), a disorder of altered 
retinal vasculature occurring frequently in low birth-weight 
infants requiring neonatal intensive care, can result in visual 
disability or permanent blindness. This condition is thought to 
be unpreventable, although it has been found to be related to 2 
major factors: Birth weight and the duration of oxygen expo-
sure.1·2·3·4·5 Retinal vasculature changes occur over time and can 
progress through a sequence of stages leading to permanent 
blindness. During this progression, the retinal vasculature reaches 
a threshold at which point the disorder might be amenable to 
surgical intervention, indicating the need for frequent and re-
peated ophthalmologic evaluations.5·6 
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Nationally, the survival of infants requiring neonatal inten-
sive care has improved over the last decade;7•8•9 this also is true 
for infants treated in Hawaii-9·10 Newer treatments, such as 
exogenous surfactant therapy for the most common, serious 
pulmonary disorder of prematurity, Respiratory Distress Syn-
drome (RDS), have contributed significantly to this improved 
survival. 11 As a result, the number of infants surviving with birth 
weights <1000 grams and gestational ages <26 weeks has 
increased. This study questioned whether improved survival of 
low birth-weight infants would be accompanied by a higher 
incidence of long-term complications such as ROP. 
Accordingly, this is a retrospective review of KMCWC's 
recent experience with infants who developed ROP in the first 
3 years after exogenous surfactant therapy was initiated in the 
Newborn Intensive Care Unit (NICU). This study focused on 
infants ~1000 grams birth weight, since these tiniest infants 
have the highest risk of death and disability. 
Materials and methods 
Retrospectively the charts were reviewed of infants with a 
diagnosis ofROP who were discharged from the NICU between 
January 1, 1989 and December 31, 1991. Demographic informa-
tion, including birth weight, gestational age, days in oxygen, 
days on mechanical ventilation and surfactant treatment was 
collected. 
INTERNATIONAL CLASSIFICATION OF RETINOPATHY OF PREMATURITY 
Figure 1. Scheme of retina of right eye (RE) and left eye (LE) showing zone 
borders and clock-hours employed to describe location and extent of retinopathy 
of prematurity. Reprinted with perrnission.21 
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ROP Classification: ROP was defined according to the Inter- groups. Chi square analysis was used to test proportional data; 
national Classification of Retinopathy of Prematurity, which .a p value of <0.05 was considered significant. Values are 
has standardized the anatomic evaluation of the disorder. This expressed as means ±standard error. 
classification describes the abnormalities of retinal develop-
ment based on location, extent of the disease and staging. 12 
ROP is reported as being located in Zone I, Zone II, and Zone 
III. During gestation, normal retinal vasculature grows from the 
optic disc outward to the periphery of the retina anteriorly in the 
eye. Zone I describes a radius extending from the optic nerve to 
twice the distance of the disc to the center of the macula. Zone 
II extends in a radius from the optic disc to the nasal ora serrata 
and temporally to the equatorial area. Zone III includes the area 
anterior to Zone II extending to the ora serrata temporally 
(Figure 1 ). The extent of the disease is expressed in clock -hours 
ofinvolvement. These clock-hours are described as the observer 
looks at that eye. 
Staging of the disease ranks the severity of abnormal vascu-
lature from Stages I to V. Stage I involves a flat white demarca-
tion line separating vascularized from avascular retina with 
abnormal branching of retinal vessels. In Stage II, the line 
becomes a ridge and extends away from the retinal surface. The 
ridge contains extraretinal fibrovascular proliferation into the 
vitreous in Stage III (Figure 2); this criterion is necessary to 
define threshold disease when considering cryosurgery. Stage 
IV is retinal detachment as the result of exudates or traction; 
Stage IV -a describes no macular involvement, while Stage IV-
b includes macular detachment. Stage V is total retinal detach-
ment. 
Plus disease designates increasing dilation and tortuosity of 
the retinal vessels with vessel engorgement in the iris, poor 
pupillary dilation and vitreous haze (Figure 3). 
Threshold disease is defined as Stage III Plus disease in Zone 
II with greater than 5 contiguous or 8 noncontiguous hours of 
extraretinal fibrovascularproliferation. Zone I with Plus disease 
is also considered threshold for treatment with cryosurgery. 
Analysis of Data: Our data were analyzed for normality of 
distribution with the goodness-of-fit test. Normally distributed 
groups were compared for significance using the student's t -test; 
the Mann-Whitney test was used for non-normally distributed 
Figure 2. Line drawing of extrarelinal fibrovascular prolif· 
eralive tissue of Stage Ill. Reprinted with permission.26 
-
Results 
There were 1,288 admissions during the review period. Four 
infants were excluded from the review because they were 
transferred from other facilities and their records were not 
complete. Another infant was deleted from the analysis involv-
ing surfactant because it was unknown whether or not she had 
received surfactant during the extended follow-up required. 
From 1989 to 1991, 87% of all NICU admissions had birth 
weights> 1000 grams • and 88% of these survived ... Thirty (3%) 
of these infants developed ROP. This group of larger ROP 
infants had a mean birth weight of 1326±64 grams; 83% weighed 
<1500 grams. Mean gestational age was 29±0.4 weeks; only 3 
infants were >31 weeks old. Stage III pre-threshold was the most 
severe stage reached; this developed in only 3 eyes. No eyes 
reached threshold or required cryosurgery. 
In the group of infants 1000 grams, 167 were admitted* 
during this 3-year period; 119 survived to discharge:· Of these 
surviving infants, 74 (62%) were diagnosed as having ROP. The 
incidence rate remained stable during the review period, ranging 
between 60% to 64% in each of the 3 years that were studied. 
The severity of ROP was related inversely to birth weight; 
threshold or greater stages were found only in infants $1000 
grams. The exceptions were the 2 surviving infants with birth 
weights <500 grams born during this period. Although both had 
mild ROP, neither reached threshold level. Overall, of the 74 
infants $1000 grams with ROP, 16 eyes (9 infants) reached 
threshold level and 14 eyes were treated with cryosurgery; the 
parents declined bilateral cryosurgery in each of twins. Demo-
graphic data for this group of infants included mean birth weight 
of775±14 grams and gestational age of26.3±0.2 weeks. They 
required oxygen for 76±4 days and ventilator therapy for 37±3 
days. The only deaths in this ROP group during this 3-year 
period occurred in 3 infants who weighed <750 grams. 
Sixty-one of the above infants with ROP also received surfac-
tant therapy for RDS during this 3-year period; 48 of these were 
Figure 3. Line drawing of extraretinal fibrovascular proliferation of amounts of 
tissue judged to be characteristic of severe Stage Ill. Reprinted with permission.'" 
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:51000 grams. There were various inclusion and exclusion 
criteria for surfactant administration, although most infants with 
documented RDS received surfactant therapy, leaving noun-
treated controls. Nevertheless, our review found 25 infants 
:51000 grams who did not meet the criteria for being given 
surfactant and were similar in many respects to the surfactant-
treated infants. This non-surfactant group was comprised of 
infants with mean birth weight of 780±30 grams and mean 
gestational age of26.2±0.3 weeks who required 77±11 days in 
oxygen and 39±8 days on mechanical ventilation. None of these 
parameters was significantly different from their surfactant-
treated counterparts. 
The number of eyes reaching threshold level was similar 
between the surfactant-(n=9) and non-surfactant- (n= 7) treated 
infants :51000 grams. Seven eyes in each group required treat-
ment with cryosurgery. There were 3 deaths in the non-surfac-
tant group, but none in the surfactant group (p = 0.01). 
The outcome of the 14 eyes treated with cryosurgery was 
determined by follow-up of 1 to 4 years. Of the 14 eyes 
undergoing cryosurgery, 6 eyes have useful vision and 8 eyes 
have no functional vision. Of the 8 eyes with no useful vision, 6 
were attributed to retinal detachment, 1 to a significant macular 
fold and 1 to severe temporal dragging of the macula. Only one 
of the 6 eyes with useful vision had a normal appearance. The 
other 5 had mild temporal dragging of the vessels and/or macula. 
Five of the 9 infants treated with cryosurgery had received 
surfactant. Seven eyes were treated in these 5 infants; 3 eyes 
(43%) have no useful vision. Of the 4 infants not receiving 
surfactant, 7 eyes had cryosurgery but 4 (57%) have no useful 
vision. 
Discussion 
This retrospective review demonstrated that 62% of NICU 
survivors with birth weights :51000 grams had ROP. The results 
suggest the incidence of ROP, including the percent of infants 
reaching threshold or worse, is similar to reports from other 
neonatal intensive care units in this country1•5•13 and around the 
world.2 
Our results further indicate that exogenous surfactant therapy 
did not have any significant effect on the incidence ofROP or on 
its severity in this small series. This conclusion is based on a 
comparison between a group of infants receiving exogenous 
surfactant therapy and a similar group not treated with surfac-
tant. While these untreated infants cannot be considered con-
trols, the groups were nevertheless similar enough to allow for 
this conclusion. Our data is in agreement with a general consen-
sus from other studies reporting the incidence ofROP in various 
large surfactant trials. 14•15•16.17•18•19•20•21 However, Repka et al ret-
rospectively reviewed 112low birth-weight infants receiving 
prophylactic surfactant treatment with lnfrasurf and demon-
strated that such therapy was associated with a decreased inci-
dence ofROP.22 
Available published follow-up data from surfactant-treated 
infants 1 and 2 years later are so far anecdotal and inconclusive. 
A review of 1,450 infants at one year of age indicated that the 
-
incidence of visual deficits ( 41 compared with 36) and blindness 
(13 compared with 12) was only slightly increased in control 
infants compared to those treated with surfactant.23 In a series of 
35 infants at 14 months adjusted age, Ferrara et al found 2 treated 
infants and 1 control infant who were blind as a result of ROP.24 
In another review25 at 2 years of age, 2 of 39 surfactant-treated 
infants were blind while none of 33 controls were blind. 
Although our small cohort makes it difficult to draw signifi-
cant conclusions, we have demonstrated that retinopathy of 
prematurity continues to be a serious problem in high-risk 
premature infants requiring NICU care at KMCWC. Infants 
with serious ROP were those :51000 grams. Sixty-two percent of 
survivors in this weight group had ROP; 12% of these infants 
(11% of affected eyes) had threshold disease. Forty-three per-
cent of the eyes of infants undergoing cryosurgery could fix and 
follow; the others had no useful vision. Exogenous surfactant 
therapy did not have an impact on the incidence or on the 
severity of ROP in our cohort. 
Although the pathogenesis of ROP is poorly understood, a 
number of multicenter clinical trials currently are underway to 
determine the value of various new therapeutic interventions 
applying both oxygen and light in order to determine the 
potential benefit in reducing the incidence of ROP. 
Footnotes 
• 31 infants admitted in 1989 were excluded because medical records not accessible. 
• 1 additional infant of unknown birth weight died and was excluded. 
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